LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on VTYX stock, giving a Buy rating today.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sam Slutsky’s rating is based on several promising developments at Ventyx Biosciences. The company has shown encouraging progress with its CNS-penetrant NLRP3 inhibitor, VTX3232, which demonstrated target engagement and safety in a Phase 2a study for early Parkinson’s disease. This success is further supported by plans to present these findings at significant medical conferences and the initiation of a placebo-controlled Phase 2 study in Parkinson’s disease, as well as evaluations in other neurodegenerative disorders like Alzheimer’s disease.
Additionally, Ventyx is advancing its peripherally restricted NLRP3 inhibitor, VTX2735, in a Phase 2 study for recurrent pericarditis, with results expected in Q4 2025. The company’s strategic focus on addressing inflammation and cardiometabolic biomarkers through innovative trials, combined with a solid financial position, underscores the potential for significant growth and development, justifying the Buy rating.
In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $9.00 price target.